Novel oral agents for multiple sclerosis

被引：5

作者：

Burton, Jodie M. ^{[1
]}

O'Connor, Paul ^{[1
]}

机构：

[1] St Michaels Hosp, Div Neurol, Multiple Sclerosis Clin, Toronto, ON M5B 1W8, Canada

来源：

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS | 2007年 / 7卷 / 03期

关键词：

D O I：

10.1007/s11910-007-0034-2

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

In 1993, interferon beta-1b, the first clinically proven disease-modifying agent for multiple sclerosis, was approved, with several comparable agents following close behind. These agents have been beneficial in reducing relapse events and MRI lesions, but all require parenteral administration, leading some otherwise eligible patients to decline such therapies. Oral agents have been studied for decades with mixed results, but a small number of medications currently being tested in phase II/III clinical trials have shown promise in efficacy and tolerability. This review assesses the results of the more thoroughly studied of these agents, some of which may soon be approved for use in multiple sclerosis.

引用

页码：223 / 230

页数：8

共 48 条

[1]

[Anonymous], 2005, Drugs R D, V6, P229

[2]

[Anonymous], RAND DOUBL BLIND PLA

[3] Mycophenolate mofetil [J].

Becker, BN .

TRANSPLANTATION PROCEEDINGS, 1999, 31 (07) :2777-2778

[4] The treatment of chronic progressive multiple sclerosis with cladribine [J].

Beutler, E ;

Sipe, JC ;

Romine, JS ;

Koziol, JA ;

McMillan, R ;

Zyroff, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (04) :1716-1720

[5] Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis [J].

Bowen, JD ;

Maravilla, K ;

Margolin, SB .

MULTIPLE SCLEROSIS JOURNAL, 2003, 9 (03) :280-283

[6] LEVAMISOLE IN MULTIPLE-SCLEROSIS, WITH SPECIAL REFERENCE TO IMMUNOLOGICAL PARAMETERS - PILOT-STUDY [J].

CENDROWSKI, W ;

CZLONKOWSKA, A .

ACTA NEUROLOGICA SCANDINAVICA, 1978, 57 (04) :354-359

[7] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

DUQUETTE, P ;

GIRARD, M ;

DESPAULT, L ;

DUBOIS, R ;

KNOBLER, RL ;

LUBLIN, FD ;

KELLEY, L ;

FRANCIS, GS ;

LAPIERRE, Y ;

ANTEL, J ;

FREEDMAN, M ;

HUM, S ;

GREENSTEIN, JI ;

MISHRA, B ;

MULDOON, J ;

WHITAKER, JN ;

EVANS, BK ;

LAYTON, B ;

SIBLEY, WA ;

LAGUNA, J ;

KRIKAWA, J ;

PATY, DW ;

OGER, JJ ;

KASTRUKOFF, LF ;

MOORE, GRW ;

HASHIMOTO, SA ;

MORRISON, W ;

NELSON, J ;

GOODIN, DS ;

MASSA, SM ;

GUTTERIDGE, E ;

ARNASON, BGW ;

NORONHA, A ;

REDER, AT ;

MARTIA, R ;

EBERS, GC ;

RICE, GPA ;

LESAUX, J ;

JOHNSON, KP ;

PANITCH, HS ;

BEVER, CT ;

CONWAY, K ;

WALLENBERG, JC ;

BEDELL, L ;

VANDENNOORT, S ;

WEINSHENKER, B ;

WEISS, W ;

REINGOLD, S ;

PACHNER, A ;

TAYLOR, W .

NEUROLOGY, 1993, 43 (04) :655-661

[8] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].

Ebers, GC ;

Rice, G ;

Lesaux, J ;

Paty, D ;

Oger, J ;

Li, DKB ;

Beall, S ;

Devonshire, V ;

Hashimoto, S ;

Hooge, J ;

Kastrukoff, L ;

Krieger, C ;

Mezei, M ;

Seland, P ;

Vorobeychi, G ;

Morrison, W ;

Nelson, J ;

Freedman, MS ;

Chrisie, S ;

Nelson, R ;

Rabinovitch, H ;

Freedman, C ;

Hartung, HP ;

Rieckmann, P ;

Archelos, J ;

Jung, S ;

Weilbach, F ;

Flachenecke, P ;

Sauer, J ;

Hommes, O ;

Jongen, P ;

Brouwer, S ;

McLeod, J ;

Pollard, J ;

Ng, R ;

Sandberg-Wollheim, M ;

Källén, K ;

Nilsson, P ;

Ekberg, R ;

Lundgren, A ;

Jadbäck, G ;

Wikström, J ;

Multanen, J ;

Valjakka, M ;

Carton, H ;

Lissoir, F ;

Declerq, I ;

Vieren, M ;

Peeters, E ;

Dubois, B .

LANCET, 1998, 352 (9139) :1498-1504

[9] Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study [J].

Filippi, M ;

Wolinsky, JS ;

Comi, G .

LANCET NEUROLOGY, 2006, 5 (03) :213-220

[10] Mycophenolate mofetil in multiple sclerosis [J].

Frohman, EM ;

Brannon, K ;

Racke, MK ;

Hawker, K .

CLINICAL NEUROPHARMACOLOGY, 2004, 27 (02) :80-83

← 1 2 3 4 5 →